Lixte Biotechnology Holdings, Inc. (LIXT)

2.4604 +0.0504 (+2.09%) 收市：04:00PM EDT

Lixte Biotechnology Holdings, Inc.

680 East Colorado Boulevard
Suite 180
Pasadena, CA 91101
United States
631 830 7092
https://lixte.com

版塊: Healthcare
行業: Biotechnology
全職員工: 3

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Bastiaan van der Baan M.Sc.	President, CEO & Chairman of the Board of Directors	172.78k	無	1972
Mr. Robert Neal Weingarten	VP & CFO	175k	無	1952
Mr. Eric J. Forman J.D.	VP & COO	200k	無	1979
Dr. James S. Miser M.D.	Chief Medical Officer	175k	無	1947

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

公司管治

截至 無 止，Lixte Biotechnology Holdings, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。